Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 246

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 246
---
 4,800 of our Depositary Shares in
connection with the offering to the underwriter, or the December 2023 Underwriter Warrants.

On February 26, 2024, in connection
with our Company’s obligations under a license agreement with Melior, we issued 14,177 Depositary Shares to Bukwang.

On April 29, 2024, in connection
with the closing of a Emtora License Agreement, we issued 15,136 Depositary Shares to Emtora.

On May 24, 2024, in connection
with the transactions contemplated by the Warrant Agreements, we issued an aggregate of 124,181 Depositary Shares to certain holders of
our Series E Warrants and Series F Warrants, upon the exercise of 62,906 Series E Warrants and 61,275 Series F Warrants, at an exercise
price of $37.50 per share. In addition, we issued to such holders an aggregate of 94,358 Series G warrants, or the Series G Warrants,
and 147,805 Series H warrants, or the Series H Warrants. The aggregate gross proceeds to the Company were approximately $6.05 million,
before deducting agent fees and expenses. Additionally, we issued warrants to purchase 6,456 of our Depositary Shares in connection with
the offering to Ladenburg, as agent, and certain designees of Ladenburg, or Warrant Agent Warrants.

| 122 |

Between December 21, 2023
and December 31, 2024, we have issued 2,477,566,800 Ordinary Shares upon the exercise of the pre-funded warrants, Series E Warrants and
Series F Warrants issued in the December 2023 underwritten public offering and private placement, including warrants exercised pursuant
to the terms of the Warrant Agreements (other than shares held in abeyance).

On July 22, 2024, we completed the Offerings with the Investors, pursuant to which we sold in the July 2024 Registered Direct Offering an aggregate of (i) 202,032 Depositary Shares and (ii) 11,157 July 2024 Pre-Funded Warrants, at a price per Depositary Share of $23.50, and a price per July 2024 Pre-Funded Warrant of $23.4975, and in the concurrent July 2024 Private Placement, we issued and sold to the Investors (x) Series